Patient Derived tumor Xenografts (PDX), a new approach of preclinical oncology.
Patient Derived tumor Xenografts (PDX)
PDX development is perfomed in partnership with our affliate Urolead.
PDX is a new approach of preclinical oncology. PDX model considers the heterogeneity of patient tumors in all its aspects (genetic, histology, molecular…).
PDX models are developed by direct transfer of surgically resected patient tumor tissue into immune-compromised mice. Xenograft tissues can be cryopreserved and thawed for drug evaluation studies.
urosphere and pdx development
+ Clinical anonymized information of patient tumor
- Informed consent received for each excised patient tumor.
- HIV, HBV, HCV, HTLV free
- Anonymized patient’s cancer clinical history.
+ PDX establishment and characterization
- Direct implant of excised patient tumors on immune-compromised mice.
- Serial passaging of tumors until obtention of stable growth patterns.
- Banking cryopreservation at early passages.
- Tumor growth, IHC and omic characterization.
- Standards of care (SoCs) efficacy data.
+ PRECLINICAL STUDIES
- Maximum Tolerated Dose studies (MTD)
- Pharmacokinetic / Pharmacodynamic studies (PK/PD)
- Antitumor Efficacy studies
Visite Urolead Website